|
![]() |
![]() Naomi KresgeFortune |
Positive results in the earliest stages of development have driven about $93 billion in market value gains this year for obesity-drug makers.
The Danish drugmaker stopped the trial halfway after a committee concluded that it hadn’t hit its goal of changing blood pressure after 12 weeks.
Europe's drugs regulator warns that the misuse of Ozempic for weight-loss is leaving diabetics struggling to get their medication.
Novo said it now plans to pour $6.8 billion into production investments this year, up from $3.9 billion in 2023.
The market for obesity treatments may soar above $80 billion by 2030 according to analysts.
The blockbuster drug from Novo Nordisk has a list price of about $1,350 per month in the US.
“These drugs are definitely an important tool, but they should not be seen as a solution to the problem,” says a WHO official who co-authored a...